News Opinion Editor's Corner TCT 2016 My Takeaways From TCT 2016: Surprises, Presuppositions, and the Gift of the Giveaway Shelley Wood November 07, 2016
News Conference News TCT 2016 No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low Shelley Wood November 07, 2016
News Industry News TCT 2016 Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions November 02, 2016
News Conference News TCT 2016 COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events Michael O'Riordan November 01, 2016
News Industry News TCT 2016 Dedicated Stent Study Conducted in Women and Minority Assesses Risks of Adverse Cardiovascular Events Following Coronary Stent Procedures November 01, 2016
News Industry News Sudy Indicates PCI Of NIRS-Defined Lipid-Rich Plaque Is Safe And Not Associated With A Greater Incidence Of Adverse Outcomes Compared To PCI of Non Lipid-Rich Plaque November 01, 2016
News Conference News TCT 2016 New BRS Studies Show Promise for Second-Generation Devices With Thinner Struts Yael L. Maxwell October 31, 2016
News Industry News TCT 2016 First Report Investigations Examine Potential For Novel Bioresorbable Stent Technologies October 31, 2016
News Industry News First-In-Human Of New Polymer-Free Stent Demonstrates Favorable Angiographic And Imaging-Based Outcomes At Nine-Months October 31, 2016
News Industry News Trial Results Suggest That Drug-Eluting Stents Are Acceptable Alternative To Open Heart Surgery For Select Patients With Left Main Coronary Artery Disease October 31, 2016
News Conference News TCT 2016 EXCEL and NOBLE: Opposing Results Pose Quandary for PCI/CABG Choice in Left Main Disease Michael O'Riordan October 31, 2016
News Conference News TCT 2016 Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI Yael L. Maxwell October 31, 2016
News Conference News TCT 2016 BIONICS: Ridaforolimus-Eluting Stent Noninferior to Zotarolimus Stent at 1 Year TCT Daily Staff October 30, 2016
News Conference News TCT 2016 LEADERS FREE: Polymer-Free DES Maintains Superior Safety, Efficacy Over BMS at 2 Years Yael L. Maxwell October 30, 2016
News Conference News TCT 2016 ‘Worrisome’ 3-Year Data From ABSORB II Raise Concerns About First-Generation Bioresorbable Stent Michael O'Riordan October 30, 2016
News Industry News Study Confirms Polymer-Free Drug-Coated Stents Safer And More Effective Than Bare-Metal Stents In Patients At Risk For Bleeding Treated With One Month Of DAPT October 30, 2016
News Industry News Very Thin-Strut Biodegradable Polymer Everolimus-Eluting And Sirolimus-Eluting Stents Shown To Be Non-Inferior To Durable Polymer Zotarolimus-Eluting Stents In All-Comers With Coronary Artery Disease October 30, 2016
News Industry News Study Finds Ridaforolimus-Eluting Stent is Non-Inferior to Zotarolimus-Eluting Stent Based On One-Year Clinical Outcomes October 30, 2016
News Conference News TCT 2016 DES With Biodegradable Polymers Stand Up Well Against Durable-Polymer Stents in the Short Term Todd Neale October 30, 2016
News Conference News TCT 2016 ILUMIEN III: OCT Imaging Matches IVUS but Fails to Beat Angiography for Stent Guidance in PCI Shelley Wood October 30, 2016